Drug Profile
CNTX 0290
Alternative Names: CNTX-0290; LY-3556050Latest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Centrexion Therapeutics; Eli Lilly and Company
- Class Anti-inflammatories; Non-opioid analgesics; Small molecules
- Mechanism of Action Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic neuropathies; Inflammatory pain; Musculoskeletal pain; Neuropathic pain
Most Recent Events
- 04 Nov 2023 Eli Lilly and Company completes a phase I pharmacokinetic trial in Healthy volunteers in USA (PO) (NCT06052462)
- 05 Oct 2023 Phase-II clinical trials in Diabetic neuropathies (In adults) in USA (PO) (NCT06074562)
- 25 Sep 2023 Eli Lilly and Company plans a phase I pharmacokinetic trial in Healthy volunteers in USA (PO) (NCT06052462),